Abbott Laboratories Corporation

Ludwig Institute for Cancer Research Limited

Peter Collins

Lloyd J Old

Gerd J Ritter

Elisabeth Stockert

Con Panousis

Antony Wilks Burgess

Webster K Cavenee

Edouard Collins Nice

Christoph Renner

Achim Jungbluth

Terrance Grant Johns

George Mark

Anne Murray

Andrew Mark Scott

Huei-Jen Su Huang

Anthony Wilks Burgess

Terrance Grant Jonhs

Huei-Jen Huang

Elizabeth Stockert

The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.

Specific binding proteins and uses thereof

Growing community of inventors

Cambridge, United Kingdom

Peter Collins